Sign in to view content

GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results

Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS

Video
Published 2022

Related

One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO
Mark R. Barakat, MD
Updates from the Field
2020
Visual Acuity and Reading With One Eye Versus Both Eyes Open in Geographic Atrophy and Associations With Patient-Reported Vision-Related Function
Jun Kong, MD, PhD
On Demand Cases, Courses, and Papers
2021
The OASIS Trial: Natural History of Symptomatic Vitreomacular Adhesion
Joseph M. Coney, MD, FASRS
Annual Meeting Talks
2016

Category: AMD-Non-Neovascular

See more